Citations (128)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ilena Pochiero, Fabrizio Calisti, Alessandro Comandini, Alessandra Del Vecchio, Isabella Costamagna, Maria Teresa Rosignoli, Agnese Cattaneo, Sasikiran Nunna, Ilaria Peduto, Franca Heiman, Hsiu-Ching Chang, Chi-Chang Chen & Christoph Correll. (2021) Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. International Journal of General Medicine 14, pages 4081-4094.
Read now
Read now
Samuel Bulteau, Marine Le Pierres, Pascal Artarit, Bastien Forestier, Emmanuelle Michaud, Anicet Chaslerie, Olivier Bonnot & Caroline Victorri-Vigneau. (2021) Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. Expert Opinion on Drug Safety 20:2, pages 225-233.
Read now
Read now
Barbara B Barton, Felix Segger, Kai Fischer, Michael Obermeier & Richard Musil. (2020) Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opinion on Drug Safety 19:3, pages 295-314.
Read now
Read now
Amir M Meftah, Elizabeth Deckler, Leslie Citrome & Joshua T Kantrowitz. (2020) New discoveries for an old drug: a review of recent olanzapine research. Postgraduate Medicine 132:1, pages 80-90.
Read now
Read now
Nicolas J. Schlienz, Andrew S. Huhn, Traci J. Speed, Mary M. Sweeney & Denis G. Antoine. (2018) Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. International Review of Psychiatry 30:5, pages 147-154.
Read now
Read now
Lenka Sušilová, Eva Češková, David Hampel, Aleš Sušil & Jan Šimůnek. (2017) Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors. International Journal of Psychiatry in Clinical Practice 21:2, pages 112-117.
Read now
Read now
L. Orsolini, C. Tomasetti, A. Valchera, R. Vecchiotti, I. Matarazzo, F. Vellante, F. Iasevoli, E. F. Buonaguro, M. Fornaro, A. L. C. Fiengo, G. Martinotti, M. Mazza, G. Perna, A. Carano, A. De Bartolomeis, M. Di Giannantonio & D. De Berardis. (2016) An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety 15:10, pages 1329-1347.
Read now
Read now
Christoffer Polcwiartek, Kristian Kragholm, Ole Schjerning, Claus Graff & Jimmi Nielsen. (2016) Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety 15:5, pages 679-688.
Read now
Read now
Philip Raskin & Anthony H. Cincotta. (2016) Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert Review of Endocrinology & Metabolism 11:2, pages 113-148.
Read now
Read now
Articles from other publishers (119)
Maria Franz, Sergi Papiol, Maria S. Simon, Barbara B. Barton, Catherine Glockner, Ilja Spellmann, Michael Riedel, Urs Heilbronner, Peter Zill, Thomas G. Schulze & Richard Musil. (2024) Association of clinical parameters and polygenic risk scores for body mass index, schizophrenia, and diabetes with antipsychotic-induced weight gain. Journal of Psychiatric Research 169, pages 184-190.
Crossref
Crossref
Prakash S. Masand, Roger S. McIntyre, Andrew J. Cutler, Michael L. Ganz, Andrea L. Lorden, Kiren Patel, Ken Kramer, Amanda Harrington & Huy-Binh Nguyen. (2023) Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records. Clinical Therapeutics.
Crossref
Crossref
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal & Margaret Hahn. (2023) Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations. Current Psychiatry Reports 25:11, pages 707-721.
Crossref
Crossref
Rizaldy C. Zapata, Dinghong Zhang, Dongmin Yoon, Chanond A. Nasamran, Daisy R. Chilin-Fuentes, Avraham Libster, Besma S. Chaudry, Mariela Lopez-Valencia, Devasena Ponnalagu, Harpreet Singh, Michael Petrascheck & Olivia Osborn. (2023) Targeting Clic1 for the treatment of obesity: A novel therapeutic strategy to reduce food intake and body weight. Molecular Metabolism 76, pages 101794.
Crossref
Crossref
J. Eder, M. S. Simon, C. Glocker & R. Musil. (2023) Gewichtszunahme unter Therapie mit PsychopharmakaWeight gain and treatment with psychotropic drugs. Der Nervenarzt.
Crossref
Crossref
Marianna Piras, Jihane Chahma, Setareh Ranjbar, Nermine Laaboub, Claire Grosu, Kerstin Jessica Plessen, Armin von Gunten, Philippe Conus & Chin Bin Eap. (2023) Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study. Schizophrenia Bulletin 49:4, pages 944-952.
Crossref
Crossref
Krzysztof Kowalski & Błażej Misiak. (2023) Schizophrenia and the COVID-19 pandemic: A narrative review from the biomedical perspective. Revista de Psiquiatría y Salud Mental.
Crossref
Crossref
Michael Leutner, Elma Dervic, Luise Bellach, Peter Klimek, Stefan Thurner & Alexander Kautzky. (2023) Obesity as pleiotropic risk state for metabolic and mental health throughout life. Translational Psychiatry 13:1.
Crossref
Crossref
Yuying Qiu, Yeqing Dong, Wei Sun, Gang Li, Mei Juan Li, Yongping Zhao, Changyong Jiang & Jie Li. (2023) Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia. Frontiers in Psychiatry 14.
Crossref
Crossref
Mina Kim, Soo Jin Yang, Hyang Hee Kim, Anna Jo, Min Jhon, Ju-Yeon Lee, Seung-Hyung Ryu, Jae-Min Kim, Young-Ran Kweon & Sung-Wan Kim. (2023) Effects of Dietary Habits on General and Abdominal Obesity in Community-dwelling Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience 21:1, pages 68-76.
Crossref
Crossref
Rizaldy C. Zapata, Dinghong Zhang, Avraham Libster, Alessandra Porcu, Patricia Montilla-Perez, Aisha Nur, Baijie Xu, Zhi Zhang, Stephanie M. Correa, Chen Liu, Francesca Telese & Olivia Osborn. (2023) Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia. Molecular Psychiatry.
Crossref
Crossref
Bea Campforts, Marjan Drukker, Joost Crins, Therese van Amelsvoort & Maarten Bak. (2023) Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open 9:1.
Crossref
Crossref
Amy C. Gross & Erika L. Nurmi. 2023. Managing Pediatric Obesity Using Advanced Therapies. Managing Pediatric Obesity Using Advanced Therapies
245
272
.
Michele Fusaroli, Emanuel Raschi, Valentina Giunchi, Marco Menchetti, Roberto Rimondini Giorgini, Fabrizio De Ponti & Elisabetta Poluzzi. (2022) Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. International Journal of Neuropsychopharmacology 25:9, pages 727-736.
Crossref
Crossref
Lukas Bergner, Hubertus Himmerich & Holger Steinberg. (2022) Die Therapie der Nahrungsverweigerung und der Anorexia nervosa in
deutschsprachigen Psychiatrie-Lehrbüchern der vergangenen 200
Jahre. Fortschritte der Neurologie · Psychiatrie.
Crossref
Crossref
Emily Smith, Nicolette Stogios, Emily Au, Kateryna Maksyutynska, Riddhita De, Andrew Ji, Mikkel Erlang Sørensen, Laura St. John, Hsiang‐Yuan Lin, Pushpal Desarkar, Yona Lunsky, Gary Remington, Margaret Hahn & Sri Mahavir Agarwal. (2022)
The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and
meta‐analysis
. Acta Psychiatrica Scandinavica 146:3, pages 201-214.
Crossref
Crossref
Nicolette Stogios, Kateryna Maksyutynska, Janani Navagnanavel, Marcos Sanches, Valerie Powell, Philip Gerretsen, Ariel Graff‐Guerrero, Araba F. Chintoh, George Foussias, Gary Remington, Margaret K. Hahn & Sri Mahavir Agarwal. (2022) Metformin for the prevention of clozapine‐induced weight gain: A retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica 146:3, pages 190-200.
Crossref
Crossref
Haishan Wu, Xijin Wang, Xuejun Liu, Hong Sang, Qijing Bo, Xiaodong Yang, Zhiyuan Xun, Keqing Li, Ruiling Zhang, Meijuan Sun, Duanfang Cai, Huaili Deng, Guijun Zhao, Juhong Li, Xianglai Liu, Guilai Zhan & Jindong Chen. (2022) Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance. Frontiers in Psychiatry 13.
Crossref
Crossref
Luisa M. Burin, Margaret K. Hahn, Neusa S. da Rocha, Therese van Amelsvoort, Agna A. Bartels-Velthuis, Richard Bruggeman, Lieuwe de Haan, Frederike Schirmbeck, Claudia J.P. Simons, Jim van Os & Wiepke Cahn. (2022) Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. Psychiatry Research 314, pages 114680.
Crossref
Crossref
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli & Christoph U. Correll. (2022) Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacology & Therapeutics 236, pages 108236.
Crossref
Crossref
Dagmar Breznoscakova & Maria Pallayova. (2022) Bipolar disorder and type 2 diabetes mellitus: A bidirectional relationship. The European Journal of Psychiatry 36:3, pages 152-162.
Crossref
Crossref
Emilia Vassilopoulou, Dimitris Efthymiou, Evangelia Papatriantafyllou, Maria Markopoulou, Efthymia-Maria Sakellariou & Alina-Codruța Popescu. (2022) Long-term metabolic and inflammatory effects of second-generation antipsychotics: A study in mentally disordered offenders. Public Health and Toxicology 2:Supplement 1.
Crossref
Crossref
Alqassem Y. Hakami, Razaz Felemban, Rami Ghazi Ahmad, Abdulrahman H. Al-Samadani, Hassan K. Salamatullah, Jamil M. Baljoon, Loay J. Alghamdi, Mostafa H. Ramadani Sindi & Mohamed Eldigire Ahmed. (2022) The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study. Frontiers in Psychiatry 13.
Crossref
Crossref
Hui Wu, Spyridon Siafis, Tasnim Hamza, Johannes Schneider-Thoma, John M Davis, Georgia Salanti & Stefan Leucht. (2022) Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin 48:3, pages 643-654.
Crossref
Crossref
Connie Jiang, Anusha Lekshminarayanan, Ihsan Balkaya, Alal Uddin, Sheital Bavishi & Eric Altschuler. (2022) Treatment of Central Vertigo With Low Dose Olanzapine: Report of Two Cases. Cureus.
Crossref
Crossref
Nicolette Stogios, Emily Smith, Sylvie Bowden, Veronica Tran, Roshanak Asgariroozbehani, William Brett McIntyre, Gary Remington, Dan Siskind, Sri Mahavir Agarwal & Margaret K. Hahn. (2021) Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology 47:3, pages 664-672.
Crossref
Crossref
В.А. Мангуби. (2021) Olanzapine: Modern Application Concepts. Психиатрия, психотерапия и клиническая психология:4, pages 699-706.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
M.P. Schuster, J. Borkent, M. Chrispijn, M. Ioannou, B. Doornbos, H. Burger & B.C.M. Haarman. (2021) Increased prevalence of metabolic syndrome in patients with bipolar disorder compared to a selected control group-a Northern Netherlands LifeLines population cohort study. Journal of Affective Disorders 295, pages 1161-1168.
Crossref
Crossref
Emilia Vassilopoulou, Dimitris Efthymiou, Evangelia Papatriantafyllou, Maria Markopoulou, Efthymia-Maria Sakellariou & Alina Codruta Popescu. (2021) Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders. Journal of Personalized Medicine 11:11, pages 1189.
Crossref
Crossref
Céline Dubath, Marianna Piras, Mehdi Gholam, Nermine Laaboub, Claire Grosu, Othman Sentissi, Franziska Gamma, Alessandra Solida, Armin von Gunten, Philippe Conus & Chin B. Eap. (2021) Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. Pharmacopsychiatry 54:06, pages 279-286.
Crossref
Crossref
Mona Gossmann, W. Scott Butsch & Ania M. Jastreboff. (2021) Treating the Chronic Disease of Obesity. Medical Clinics of North America 105:6, pages 983-1016.
Crossref
Crossref
Svenja Davis-Glurich, Bettina Haas, Karin Thume & Dieter F. Braus. (2021) Primäre Psychose und Typ-2-DiabetesPrimary psychosis and type 2 diabetes. Der Diabetologe 17:7, pages 739-743.
Crossref
Crossref
Vikas Menon & Samir K Praharaj. (2021) Management of Drug-induced Weight Gain in Persons Receiving Psychotropic Drugs. Indian Journal of Private Psychiatry 15:1, pages 10-16.
Crossref
Crossref
Roni F Kunst, Audrie L Langlais, Deborah Barlow, Karen L Houseknecht & Katherine J Motyl. (2021)
Housing Temperature Influences Atypical Antipsychotic Drug‐Induced Bone Loss in Female
C57BL
/
6J
Mice
. JBMR Plus 5:10.
Crossref
Crossref
Sinay Onen & Ibrahim Taymur. (2021) Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia. Journal of Psychopharmacology 35:9, pages 1120-1126.
Crossref
Crossref
Rong Li, Wenqiang Zhu, Piaopiao Huang, Yang Yang, Fei Luo, Wen Dai, Li Shen, Wenjing Pei & Xiansheng Huang. (2021) Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomedicine & Pharmacotherapy 141, pages 111803.
Crossref
Crossref
Jia Hong Liu, Nan Chen, Yan Hong Guo, Xiao Ni Guan, Jun Wang, Dong Wang & Mei Hong Xiu. (2021) Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. Journal of Psychiatric Research 140, pages 409-415.
Crossref
Crossref
Natalia Jimeno, Veronica Velasco-Gonzalez, Inmaculada Fierro, Mercedes Duran & Alfonso Carvajal. (2021) Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study. Scientific Reports 11:1.
Crossref
Crossref
Jana Osacka, Romana Koprdova, Andrej Tillinger, Zdenko Pirnik & Alexander Kiss. (2021) Haloperidol and aripiprazole impact on the BDNF and glucocorticoid receptor levels in the rat hippocampus and prefrontal cortex: effect of the chronic mild stress. Endocrine Regulations 55:3, pages 153-162.
Crossref
Crossref
Yi Su, Hao Yan, Liangkun Guo, Tianlan Lu, Dai Zhang & Weihua Yue. (2021) Association of MTHFR C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index. Frontiers in Psychiatry 12.
Crossref
Crossref
Mark R. Libowitz & Erika L. Nurmi. (2021) The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. Frontiers in Psychiatry 12.
Crossref
Crossref
Carla Carnovale, Ersilia Lucenteforte, Vera Battini, Faizan Mazhar, Marco Fornili, Elena Invernizzi, Giulia Mosini, Michele Gringeri, Annalisa Capuano, Cristina Scavone, Maria Nobile, Chiara Vantaggiato, Simone Pisano, Carmela Bravaccio, Sonia Radice, Emilio Clementi & Marco Pozzi. (2021) Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychological Medicine, pages 1-13.
Crossref
Crossref
Maarten Bak, Marjan Drukker, Shauna Cortenraad, Emma Vandenberk & Sinan Guloksuz. (2021) Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 16:2, pages e0244944.
Crossref
Crossref
Sneha Singh, Maria L. Ricardo‐Silgado, Suzette J. Bielinski & Andres Acosta. (2021) Pharmacogenomics of Medication‐Induced Weight Gain and Antiobesity Medications. Obesity 29:2, pages 265-273.
Crossref
Crossref
Heidi N. Boyda, Ric M. Procyshyn, Lurdes Tse, Jessica W. Y. Yuen, William G. Honer & Alasdair M. Barr. (2021) A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLOS ONE 16:1, pages e0246211.
Crossref
Crossref
Nicolette Stogios, Emily Smith, Roshanak Asgariroozbehani, Laurie Hamel, Alexander Gdanski, Peter Selby, Sanjeev Sockalingam, Ariel Graff-Guerrero, Valerie Taylor, Sri Agarwal & Margaret Hahn. (2020) Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. Nutrients 12:12, pages 3883.
Crossref
Crossref
Dragos C. Ragazan, Jonas Eberhard & Jonas Berge. (2020) Sex-Specific Associations Between Bipolar Disorder Pharmacological Maintenance Therapies and Inpatient Rehospitalizations: A 9-Year Swedish National Registry Study. Frontiers in Psychiatry 11.
Crossref
Crossref
A. Vignapiano, A. Mautone, L. Vitulano & G. Corrivetti. (2020) P.836Metabolic syndrome and long-acting injected (LAI) preparations in schizophrenia: a "real-world" study. European Neuropsychopharmacology 40, pages S465.
Crossref
Crossref
Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath & Rituparna Maiti. (2020) Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology 237:11, pages 3471-3480.
Crossref
Crossref
Rizaldy C. Zapata, Sara Brin Rosenthal, Kathleen Fisch, Khoi Dao, Mohit Jain & Olivia Osborn. (2020) Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain. Scientific Reports 10:1.
Crossref
Crossref
Francesca Forno, Yossi Maatuf, Shatha Boukeileh, Priya Dipta, Mohamed Mahameed, Odai Darawshi, Vitor Ferreira, Patricia Rada, Irma García-Martinez, Einav Gross, Avi Priel, Ángela M. Valverde & Boaz Tirosh. (2020) Aripiprazole Cytotoxicity Coincides with Activation of the Unfolded Protein Response in Human Hepatic Cells. Journal of Pharmacology and Experimental Therapeutics 374:3, pages 452-461.
Crossref
Crossref
Barbara B. Barton, Anja Zagler, Katharina Engl, Leonie Rihs & Richard Musil. (2019) Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. European Archives of Psychiatry and Clinical Neuroscience 270:5, pages 597-609.
Crossref
Crossref
Valéria de Almeida, Guilherme L. Alexandrino, Adriano Aquino, Alexandre F. Gomes, Michael Murgu, Henrik Dobrowolny, Paul C. Guest, Johann Steiner & Daniel Martins-de-Souza. (2020) Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 101, pages 109945.
Crossref
Crossref
Albert Martínez-Pinteño, Susana García-Cerro, Sergi Mas, Teresa Torres, Daniel Boloc, Natalia Rodríguez, Amalia Lafuente, Patricia Gassó, Joan Albert Arnaiz & Eduard Parellada. (2020) The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. Journal of Psychiatric Research 126, pages 8-18.
Crossref
Crossref
Michael Schneider, Philipp Pauwels, Sermin Toto, Stefan Bleich, Renate Grohmann, Martin Heinze & Timo Greiner. (2020) Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016. European Neuropsychopharmacology 36, pages 60-71.
Crossref
Crossref
Mahyar Etminan, Gary S. Collins & Mohammad Ali Mansournia. (2020) Using Causal Diagrams to Improve the Design and Interpretation of Medical Research. Chest 158:1, pages S21-S28.
Crossref
Crossref
Larissa Doretto, Flora Chaves Mari & Ana Cristina Chaves. (2020) Polycystic Ovary Syndrome and Psychotic Disorder. Frontiers in Psychiatry 11.
Crossref
Crossref
Sophie E ter Hark, Stéphane Jamain, Dick Schijven, Bochao D Lin, Mark K Bakker, Anne Boland-Auge, Jean-François Deleuze, Réjane Troudet, Anil K Malhotra, Sinan Gülöksüz, Christiaan H Vinkers, Bjørn H Ebdrup, René S Kahn, Marion Leboyer & Jurjen J Luykx. (2020) A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal of Psychopharmacology 34:5, pages 524-531.
Crossref
Crossref
Juan Antonio García-Carmona, Jorge Simal-Aguado, María Pilar Campos-Navarro, Francisco Valdivia-Muñoz & Alejandro Galindo-Tovar. (2020) Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study. Clinical Drug Investigation 40:5, pages 459-468.
Crossref
Crossref
Anastasiya Nestsiarovich, Berit Kerner, Aurélien J. Mazurie, Daniel C. Cannon, Nathaniel G. Hurwitz, Yiliang Zhu, Stuart J. Nelson, Tudor I. Oprea, Annette S. Crisanti, Mauricio Tohen, Douglas J. Perkins & Christophe G. Lambert. (2020) Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology 112, pages 104511.
Crossref
Crossref
Virginio Salvi, Andrea Aguglia, Francesco Barone-Adesi, Davide Bianchi, Chiara Donfrancesco, Filippo Dragogna, Luigi Palmieri, Gianluca Serafini, Mario Amore & Claudio Mencacci. (2020) Cardiovascular risk in patients with severe mental illness in Italy. European Psychiatry 63:1.
Crossref
Crossref
Yang Tian, Dianying Liu, Dongmei Wang, Jiesi Wang, Hang Xu, Qilong Dai, Elena C. Andriescue, Hanjing E. Wu, Meihong Xiu, Dachun Chen, Li Wang, Yiwen Chen, Ruilang Yang, Anshi Wu, Chang Wei Wei & Xiangyang Zhang. (2020) Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. Schizophrenia Research 215, pages 270-276.
Crossref
Crossref
Michael Hawkins, Samantha E. Leung, Andrew Lee, Susan Wnuk, Stephanie Cassin, Raed Hawa & Sanjeev Sockalingam. (2020) Psychiatric Medication Use and Weight Outcomes One Year After Bariatric Surgery. Psychosomatics 61:1, pages 56-63.
Crossref
Crossref
Shengying Qin, Jingsong Ma, Cong Huai & Wei Zhou. 2020. Pharmacogenomics in Precision Medicine. Pharmacogenomics in Precision Medicine
107
122
.
Carley MacRae. 2020. Adolescent Nutrition. Adolescent Nutrition
103
140
.
Oliver FreudenreichOliver Freudenreich. 2020. Psychotic Disorders. Psychotic Disorders
335
350
.
Peifan Li, Yiming Wang, Xingde Liu, Zhen Zhou, Jun Wang, Haiyan Zhou, Lei Zheng & Lixia Yang. (2019) Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling. BMC Pharmacology and Toxicology 20:1.
Crossref
Crossref
Elena G. Kornetova, Alexander N. Kornetov, Irina A. Mednova, Viktoria V. Dubrovskaya, Anastasia S. Boiko, Nikolay A. Bokhan, Anton J. M. Loonen & Svetlana A. Ivanova. (2019) Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. Frontiers in Psychiatry 10.
Crossref
Crossref
Pełka-Wysiecka, Kaczmarczyk, Bąba-Kubiś, Liśkiewicz, Wroński, Skonieczna-Żydecka, Marlicz, Misiak, Starzyńska, Kucharska-Mazur, Łoniewski & Samochowiec. (2019) Analysis of Gut Microbiota and Their Metabolic Potential in Patients with Schizophrenia Treated with Olanzapine: Results from a Six-Week Observational Prospective Cohort Study. Journal of Clinical Medicine 8:10, pages 1605.
Crossref
Crossref
Philipp Homan, Miklos Argyelan, Christina L. Fales, Anita D. Barber, Pamela DeRosse, Philip R. Szeszko, Delbert G. Robinson, Todd Lencz & Anil K. Malhotra. (2019) Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis. Neuropsychopharmacology 44:11, pages 1948-1954.
Crossref
Crossref
Xueli Zhang, Yi Zhao, Hua Shao & Xiao Zheng. (2019) Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes. Psychoneuroendocrinology 108, pages 163-171.
Crossref
Crossref
Gary SchneiderTobias BanaschewskiBrian L. FeldmanPer A. GustafssonBrian MurphyMatthew ReynoldsDavid R. CoghillWilliam M. Spalding. (2019) Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy. Journal of Child and Adolescent Psychopharmacology 29:4, pages 285-304.
Crossref
Crossref
Wei Zhou, Yong Xu, Qinyu Lv, Yong-hui Sheng, Luan Chen, Mo Li, Lu Shen, Cong Huai, Zhenghui Yi, Donghong Cui & Shengying Qin. (2019) Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients. Frontiers in Pharmacology 10.
Crossref
Crossref
Olivia Currie, Jonathan Williman, Dee Mangin, Bianca McKinnon-Gee & Paul Bridgford. (2019) Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design. BMJ Open 9:2, pages e022984.
Crossref
Crossref
Antonio Ventriglio, Ross J. Baldessarini, Giovanna Vitrani, Iris Bonfitto, Angela Chiara Cecere, Angelo Rinaldi, Annamaria Petito & Antonello Bellomo. (2019) Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. Frontiers in Psychiatry 9.
Crossref
Crossref
Wolfgang Gaebel, Alkomiet Hasan & Peter Falkai. 2019. S3-Leitlinie Schizophrenie. S3-Leitlinie Schizophrenie
51
137
.
Paul C. Guest. 2019. Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders. Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders
1
16
.
Leon I. Igel. 2019. Obesity Management. Obesity Management
61
67
.
Gordon Ferns. (2018) Cause, consequence or coincidence: The relationship between psychiatric disease and metabolic syndrome. Translational Metabolic Syndrome Research 1, pages 23-38.
Crossref
Crossref
Robert C. Smith, Lawrence Maayan, Renrong Wu, Mary Youssef, Zhihui Jing, Henry Sershen, Victoria Szabo, Jordan Meyers, Hua Jin, Jinping Zhao & John M. Davis. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology 235:12, pages 3545-3558.
Crossref
Crossref
David PJ Osborn, Irene Petersen, Nick Beckley, Kate Walters, Irwin Nazareth & Joseph Hayes. (2018) Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. Journal of Psychopharmacology 32:10, pages 1098-1103.
Crossref
Crossref
Priyanthi B. Gjerde, Ingrid Dieset, Carmen Simonsen, Eva Z. Hoseth, Trude Iversen, Trine V. Lagerberg, Siv Hege Lyngstad, Ragni H. Mørch, Silje Skrede, Ole A. Andreassen, Ingrid Melle & Vidar M. Steen. (2018) Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. Schizophrenia Research 197, pages 253-260.
Crossref
Crossref
Thiago Duarte, Fernanda Barbisan, Pedro Antônio Schmidt do Prado-Lima, Verônica Farina Azzolin, Ivo Emílio da Cruz Jung, Marta Maria Medeiros Frescura Duarte, Cibele Ferreira Teixeira, Moises Henrique Mastella & Ivana Beatrice Mânica da Cruz. (2018) Ziprasidone, a second-generation antipsychotic drug, triggers a macrophage inflammatory response in vitro. Cytokine 106, pages 101-107.
Crossref
Crossref
Adriano Aquino, Guilherme L. Alexandrino, Paul C. Guest, Fabio Augusto, Alexandre F. Gomes, Michael Murgu, Johann Steiner & Daniel Martins-de-Souza. (2018) Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. Frontiers in Psychiatry 9.
Crossref
Crossref
Jacob S Ballon, Utpal B Pajvani, Laurel ES Mayer, Zachary Freyberg, Robin Freyberg, Ignacio Contreras, Michael Rosenbaum, Rudolph L Leibel & Jeffrey A Lieberman. (2018) Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. Journal of Psychopharmacology 32:5, pages 533-540.
Crossref
Crossref
Ching-Hua Lin, Shih-Chi Lin, Yu-Hui Huang, Fu-Chiang Wang & Chun-Jen Huang. (2018) Early prediction of olanzapine-induced weight gain for schizophrenia patients. Psychiatry Research 263, pages 207-211.
Crossref
Crossref
Eduard Vieta & José Manuel Montes. (2017) A Review of Asenapine in the Treatment of Bipolar Disorder. Clinical Drug Investigation 38:2, pages 87-99.
Crossref
Crossref
Christina Engelke, Christian Lange-Asschenfeldt, Stephanie Peter, Kai G. Kahl, Karel Frasch, Jens I. Larsen, Graziella G. Bickel, Bernhard Bork, Bent A. Jacobsen, Signe O. Wallenstein-Jensen, Christoph Lauber, Birthe Mogensen, Jørgen A. Nielsen, Wulf Rössler, Kenji J. Tsuchiya, Kristian L. Toftegaard, Ulla A. Andersen, Richard Uwakwe, Povl Munk-Jørgensen & Joachim Cordes. (2020) A cross-continental analysis of weight gain, psychiatric diagnoses and medication use during inpatient psychiatric treatment. The international study on physical illness in mentally ill. European Psychiatry 48:1, pages 65-70.
Crossref
Crossref
Steven C. Stoner. (2017) Management of serious cardiac adverse effects of antipsychotic medications. Mental Health Clinician 7:6, pages 246-254.
Crossref
Crossref
Vidar M. Steen, Silje Skrede, Tatiana Polushina, Miguel López, Ole A. Andreassen, Johan Fernø & Stephanie Le Hellard. (2017) Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. European Neuropsychopharmacology 27:6, pages 589-598.
Crossref
Crossref
Tom MunyerBrittany Finocchio. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Leon I. Igel, Rekha B. Kumar, Katherine H. Saunders & Louis J. Aronne. (2017) Practical Use of Pharmacotherapy for Obesity. Gastroenterology 152:7, pages 1765-1779.
Crossref
Crossref
Leila Jahangard, Shahrokh Akbarian, Mohammad Haghighi, Mohammad Ahmadpanah, Amir Keshavarzi, Hafez Bajoghli, Dena Sadeghi Bahmani, Edith Holsboer-Trachsler & Serge Brand. (2017) Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed – Results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Research 251, pages 182-191.
Crossref
Crossref
Dennis M. StyneSilva A. ArslanianEllen L. ConnorIsmaa Sadaf FarooqiM. Hassan MuradJanet H. Silverstein & Jack A. Yanovski. (2017) Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 102:3, pages 709-757.
Crossref
Crossref
H. Dreber, S. Reynisdottir, B. Angelin, P. Tynelius, F. Rasmussen & E. Hemmingsson. (2017) Mental distress in treatment seeking young adults (18-25 years) with severe obesity compared with population controls of different body mass index levels: cohort study. Clinical Obesity 7:1, pages 1-10.
Crossref
Crossref
Varuni Asanka de Silva, Chathurie Suraweera, Suhashini S. Ratnatunga, Madhubashinee Dayabandara, Nimali Wanniarachchi & Raveen Hanwella. (2016) Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 16:1.
Crossref
Crossref
Hui Fang, Yan Feng Zhen, Xing Yu Liu, Gang Xu, Jair C. Soares, Jingping Zhao & Xiang Yang Zhang. (2016) Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls. International Clinical Psychopharmacology 31:6, pages 353-357.
Crossref
Crossref
R-R Wu, F-Y Zhang, K-M Gao, J-J Ou, P Shao, H Jin, W-B Guo, P K Chan & J-P Zhao. (2016) Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Molecular Psychiatry 21:11, pages 1537-1544.
Crossref
Crossref
Marco Solmi, Nicola Veronese, Leonardo Zaninotto, Marc L. M. van der Loos, Keming Gao, Ayal Schaffer, Catherine Reis, Claus Normann, Ion-George Anghelescu & Christoph U. Correll. (2016) Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectrums 21:5, pages 403-418.
Crossref
Crossref
Scott Auerbach, Dayne Filer, David Reif, Vickie Walker, Alison C. Holloway, Jennifer Schlezinger, Supriya Srinivasan, Daniel Svoboda, Richard Judson, John R. Bucher & Kristina A. Thayer. (2016) Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data. Environmental Health Perspectives 124:8, pages 1141-1154.
Crossref
Crossref
Joyce Wei Xin Chong, Earl Hsien-Jie Tan, Chia Eng Chong, Yiwei Ng & Ruki Wijesinghe. (2016) Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Mental Health Clinician 6:4, pages 178-184.
Crossref
Crossref
David Arterburn, G. Craig Wood, Mary Kay Theis, Emily O. Westbrook, Jane Anau, Margaret Rukstalis, Joseph A. Boscarino, Zahra Daar & Glenn S. Gerhard. (2016) Antipsychotic medications and extreme weight gain in two health systems. Obesity Research & Clinical Practice 10:4, pages 408-423.
Crossref
Crossref
Louise Benarroch, Chantel Kowalchuk, Virginia Wilson, Celine Teo, Melanie Guenette, Araba Chintoh, Yasika Nesarajah, Valerie Taylor, Peter Selby, Paul Fletcher, Gary J. Remington & Margaret K. Hahn. (2016) Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology 233:14, pages 2629-2653.
Crossref
Crossref
Hao Yu, Lifang Wang, Luxian Lv, Cuicui Ma, Bo Du, Tianlan Lu, Chao Jin, Hao Yan, Yongfeng Yang, Wenqiang Li, Yanyan Ruan, Hongyan Zhang, Hongxing Zhang, Weifeng Mi, Bryan Mowry, Wenbin Ma, Keqing Li, Dai Zhang & Weihua Yue. (2016)
Genome-Wide Association Study Suggested the
PTPRD
Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications
. Schizophrenia Bulletin 42:3, pages 814-823.
Crossref
Crossref
Qi-Jing Bo, Zhi-Min Wang, Xian-Bin Li, Xin Ma, Chuan-Yue Wang & Jose de Leon. (2016) Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Research 237, pages 257-263.
Crossref
Crossref
Hoi Lun Cheng, Sharon Medlow & Katharine Steinbeck. (2016) The Health Consequences of Obesity in Young Adulthood. Current Obesity Reports 5:1, pages 30-37.
Crossref
Crossref
Jianjun Cheng, Patrick M. Giguere, Claire M. Schmerberg, Vladimir M. Pogorelov, Ramona M. Rodriguiz, Xi-Ping Huang, Hu Zhu, John D. McCorvy, William C. Wetsel, Bryan L. Roth & Alan P. Kozikowski. (2016) Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. Journal of Medicinal Chemistry 59:2, pages 578-591.
Crossref
Crossref
Jui-Fen Cheng, Xuan-Yi Huang, Te-Le Liu, Ruey-Yun Wang & Han-Yi Ching. (2016) The Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with Schizophrenia. Evidence-Based Complementary and Alternative Medicine 2016, pages 1-9.
Crossref
Crossref
P. Chue & J. Chue. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
35
54
.
Valentina Medici, Stephen A. McClave & Keith R. Miller. (2015) Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity. Current Gastroenterology Reports 18:1.
Crossref
Crossref
Maria G. Valdovinos. 2016. Behavioral Health Promotion and Intervention in Intellectual and Developmental Disabilities. Behavioral Health Promotion and Intervention in Intellectual and Developmental Disabilities
1
19
.
Varuni A de Silva, Madhubhashinee Dayabandara, Hiranya Wijesundara, Thushani Henegama, Heshan Gunewardena, Chathurie Suraweera & Raveen Hanwella. (2015) Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. Journal of Psychopharmacology 29:12, pages 1255-1261.
Crossref
Crossref
Michael J. Waterson & Tamas L. Horvath. (2015) Neuronal Regulation of Energy Homeostasis: Beyond the Hypothalamus and Feeding. Cell Metabolism 22:6, pages 962-970.
Crossref
Crossref
Jianjun Cheng & Alan P. Kozikowski. (2015)
We Need 2C but Not 2B: Developing Serotonin 2C (5-HT
2C
) Receptor Agonists for the Treatment of CNS Disorders
. ChemMedChem 10:12, pages 1963-1967.
Crossref
Crossref
Sarah R. Shelby, Susan Labott & Rebecca A. Stout. (2015) Bariatric surgery: a viable treatment option for patients with severe mental illness. Surgery for Obesity and Related Diseases 11:6, pages 1342-1348.
Crossref
Crossref
Guy Faulkner & Mark Duncan. (2015) Metformin to reduce weight gain and metabolic disturbance in schizophrenia. Evidence Based Mental Health 18:3, pages 89-89.
Crossref
Crossref
Myung-Seon SongWoong HahmSeong-Yong ParkKye-Hyen HongIn-Ho Paik. (2015) Obesity and Psychopathology of Inpatients with Schizophrenia. Journal of Korean Neuropsychiatric Association 54:2, pages 172.
Crossref
Crossref
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli & Christoph Correll. (2022) Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia. SSRN Electronic Journal.
Crossref
Crossref